Study of a New Medical Device in Gel Formulation Versus Calgel® for the Topical Treatment of Teething in Infants
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open label, parallel-groups, multicenter study. The study will be
conducted in three clinical sites. Test Medical Device: 0.54% Hyaluronic Acid rose honey
flavour gel medical device class IIa.
Phase:
Phase 3
Details
Lead Sponsor:
Ricerfarma S.r.l
Collaborators:
Latis S.r.l. Opera Contract Research Organization SRL Opera CRO, a TIGERMED Group Company